Advertisement
Disease Research
Subscribe to Disease Research

The Lead

Profectus BioSciences Snags $3.5M from NIH for HIV Vaccines

July 30, 2014 2:41 pm | News | Comments

Profectus BioSciences announced the award of two SBIR grants totaling $3.5 million from the Division of AIDS, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH). Read more...        

Treatment Combo Benefits Lung Cancer Patients

July 30, 2014 2:04 pm | News | Comments

A combination of the EGFR-targeted anticancer therapeutics Gilotrif and Erbitux yielded clinical...

New Route to ID Bacterial Infection Drugs

July 30, 2014 1:41 pm | News | Comments

About 100 drugs already approved by the FDA for other purposes can also prevent the growth of...

Diabetes Drugs Get Positive CHMP Opinions for CV Safety Updates

July 30, 2014 10:58 am | News | Comments

Takeda Pharmaceuticals International GmbH announced that the Committee for Medicinal Products...

View Sample

FREE Email Newsletter

Daily news and top headlines for drug research professionals

AstraZeneca, Kyowa Hakko Kirin Partner on Immuno-Oncology Study

July 30, 2014 10:48 am | News | Comments

AstraZeneca announced that it has entered into a clinical study collaboration with Kyowa Hakko Kirin for a Phase 1/1b immuno-oncology study that will evaluate the safety and efficacy of two separate combinations of three investigational compounds in multiple solid tumors. Read more...

European Commission Approves Eliquis for DVT, PE

July 30, 2014 10:37 am | News | Comments

Bristol-Myers Squibb Co. and Pfizer Inc. announced that the European Commission has approved Eliquis (apixaban) for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and the prevention of recurrent DVT and PE in adults. Read more...

Researchers to Study BRCA1-Related Breast Cancer

July 30, 2014 10:26 am | by Ashley WennersHerron, Virginia Tech | News | Comments

Deborah Kelly and Zhi Sheng, assistant professors at the Virginia Tech Carilion Research Institute, recently received a grant from the Commonwealth Health Research Board to investigate hereditary breast cancer, an effort that may lead to new treatment approaches. Read more...

Advertisement

Cancer Challenge Attracts Anonymous $100M Gift

July 29, 2014 2:54 pm | News | Comments

Oregon Health & Science University’s Knight Cancer Institute has received a $100 million gift to fuel its ambitious vision to stop cancer in its tracks. Read more...                       

Neurotrope Initiates Phase 2a Alzheimer's Treatment Study

July 29, 2014 2:48 pm | News | Comments

Neurotrope Inc. announced that it has initiated a Phase 2a clinical trial to evaluate bryostatin for the treatment of patients with Alzheimer's disease (AD). Read more...                       

Forced Mutations Doom HIV

July 29, 2014 2:32 pm | News | Comments

Fifteen years ago, researchers thought if they could induce the HIV virus to mutate uncontrollably, they could force it to weaken and eventually die out. But in a 2011 clinical trial, a drug based on this method did not eliminate the virus from patients. Now, researchers are aiming to develop better versions of that drug. Read more...

$1,000 Sovaldi Now Choice Hep C Treatment

July 29, 2014 12:28 pm | by Ricardo Alonso-Zaldivar | News | Comments

The price may be high but so is demand. A new $1,000-per-pill drug has become the treatment of choice for Americans with hepatitis C, a liver-wasting disease that affects more than 3 million. Read more...             

Glaucoma Drug Gets EU Approval

July 29, 2014 11:18 am | News | Comments

Alcon, the global leader in eye care and a division of Novartis, announced that Simbrinza eye drops suspension has been approved by the European Commission to decrease elevated intraocular pressure in adult patients with open-angle glaucoma or ocular hypertension, for which monotherapy provides insufficient IOP reduction. Read more...

Advertisement

Artes, Burnet Institute Partner on Malaria Vaccine

July 29, 2014 11:13 am | by Catherine Somerville | News | Comments

Artes Biotechnology and Burnet Institute have joined forces to develop a new type of malaria vaccine in a project funded by the PATH Malaria Vaccine Initiative (MVI), which will produce purified vaccine antigens as virus-like particles, a type of nano-particle, for testing in laboratory studies. Read more...

European Commission Approves Leukemia Drug

July 29, 2014 11:04 am | News | Comments

Roche announced that the European Commission has approved Gazyvaro (obinutuzumab) in combination with chlorambucil chemotherapy for the treatment of people with previously untreated chronic lymphocytic leukemia who have comorbidities making them unsuitable for an intensive therapy (full-dose fludarabine based therapy). Read more...

Merck Serono Kicks Off Study of Merkel Cell Carcinoma Drug

July 29, 2014 10:59 am | News | Comments

Merck Serono, the biopharmaceutical division of Merck, announced the initiation of an international Phase 2 study designed to assess the efficacy and safety of MSB0010718C, an investigational fully human IgG1 monoclonal antibody that binds to programmed death-ligand 1 (PD-L1). Read more...

Biologists Think Stem Cells May “Talk” to Each Other

July 29, 2014 10:47 am | News | Comments

Biologists at the University of Sheffield’s Centre for Stem Cell Biology led by Prof. Peter Andrews and engineers in the Complex Systems and Signal Processing Group led by Prof. Daniel Coca have completed a landmark study of human pluripotent stem cells. Read more...

AstraZeneca, QIAGEN Collaborate on Iressa Diagnostic Test

July 28, 2014 12:38 pm | News | Comments

AstraZeneca announced that it has entered into a collaboration with Netherlands-based QIAGEN to develop a non-invasive diagnostic test to identify non-small cell lung cancer patients who are suitable for treatment with Iressa. Read more...    

Advertisement

Scientists Discover New Mechanism of Drug Resistance

July 28, 2014 12:31 pm | News | Comments

Microorganisms can evade treatment by acquiring mutations in the genes targeted by antibiotics or antifungal drugs. Now, a new study has shown that microorganisms can use a temporary silencing of drug targets to gain the benefits of drug resistance without the commitment. Read more...

Cancer Drug Shows Promise as Infertility Treatment

July 28, 2014 12:26 pm | News | Comments

Physicians may have a new drug to treat infertility in women with polycystic ovary syndrome, according to a national, multi-center clinical trial. Read more...                          

HIV Inhibitor May Also Block Herpes Infection

July 28, 2014 12:19 pm | News | Comments

Creating a successful vaccine against two members of the herpes virus family, the sexually transmitted herpes simplex virus 1 (HSV-1) and 2 (HSV-2), has proven to be challenging. But now, a clinical trial, based on an HSV-2 vaccine, is being conducted. Read more...

FDA Clears IND for Lorus Blood Cancer Drug

July 28, 2014 10:53 am | News | Comments

Lorus Therapeutics Inc. announced that the FDA completed its review and cleared the company's IND application of LOR-253 for the treatment of hematologic malignancies including acute myeloid leukemia, high-risk myelodysplastic syndromes, lymphomas and multiple myeloma. Read more...

Veloxis Gets EU Marketing Authorization for Transplant Drug

July 28, 2014 10:47 am | News | Comments

Veloxis Pharmaceuticals A/S and Chiesi Farmaceutici S.p.A. announced that the European Commission (EC) has granted marketing authorization for Envarsus for the prevention of organ rejection in adult kidney and liver transplant patients in the European Union (EU). Read more...

AstraZeneca, Roche Collaborate on Companion Diagnostic Test

July 28, 2014 10:41 am | News | Comments

AstraZeneca announced it has entered into collaboration with Roche to develop a plasma-based companion diagnostic test to support AZD9291, AstraZeneca’s investigational compound in clinical development for non-small-cell lung cancer (NSCLC). Read more...

COSMOS Results Published on World Hepatitis Day

July 28, 2014 10:35 am | News | Comments

Medivir AB announced that results from the phase 2 COSMOS clinical study were published in The Lancet, demonstrating that 92% of genotype 1 chronic hepatitis C virus adult patients treated with simeprevir in combination with sofosbuvir achieved sustained virologic response 12 weeks after the end of treatment. Read more...

TTP Labtech Technology IDs Novel Drug Candidates for Neuropsychiatric Disorders

July 25, 2014 2:50 pm | News | Comments

The first high-resolution X-ray crystal structure of the metabotropic glutamate receptor 5 transmembrane domain was reported in Nature this week. The work was performed at Heptares Therapeutics using TTP Labtech’s innovative liquid handling technology for lipidic cubic phase crystallography. Read more...

SRI Snags NIH Contract for HIV, AIDS Therapies

July 25, 2014 2:47 pm | News | Comments

SRI International has been awarded a new $49 million, seven-year contract with the NIAID, part of the NIH, to conduct preclinical development of potential therapies for HIV infection and AIDS. Read more...              

EPFL, Nearmedic Pharma Partner to Fight Tuberculosis

July 25, 2014 2:42 pm | News | Comments

The pharmaceutical company Nearmedic is collaborating with EPFL to participate in the development of a treatment against tuberculosis. Read more...                             

‘Broken Genes’ for a Broken System

July 25, 2014 2:30 pm | News | Comments

The recent discovery of a genetic mutation that protects against type 2 diabetes may offer hope in fighting more than just diabetes. It also illustrates how using the tools of genetics to hunt for “broken genes” can aid drug discovery, according to a Harvard professor. Read more...

More U.S. Girls Now Getting Cervical Cancer Vaccine

July 25, 2014 2:20 pm | News | Comments

More teen girls are getting a controversial cervical cancer vaccine but the increase isn't much of a bump, the government reported Thursday. Read more...                            

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading